NRx Pharmaceuticals $11.18M DARPA Award, What the SPARC-TMS Depression Trial Means

NRx Pharmaceuticals, Inc. has announced an $11,177,757.27 DARPA contract to fund a clinical trial of its investigational drug NRX-101 combined with robotic transcranial magnetic stimulation (TMS) in adults with treatment-resistant depression.

NRx announced the award on September 30, 2026, through its subsidiary NRx Defense Systems. The study, called SPARC-TMS, is registered on ClinicalTrials.gov as NCT07227103. It is a randomized, double-blind Phase 2/3 trial with an estimated enrollment of 400 participants.

The key point for patients and families: this is funding for clinical research, not an FDA approval of NRX-101 for depression. NRX-101 is still an investigational drug in this study. There is also no class action, settlement, claim form or compensation program tied to this award.

NRx Pharmaceuticals $11.18M DARPA Award: Quick Facts

Fact	Details
Company	NRx Pharmaceuticals, Inc.
Subsidiary receiving the award	NRx Defense Systems, Inc.
Government agency	Defense Advanced Research Projects Agency (DARPA)
Contract amount	$11,177,757.27 (initial contract)
Announcement date	September 30, 2026
Project	SPARC-TMS
ClinicalTrials.gov number	NCT07227103
Trial phase	Phase 2/3
Design	Randomized, double-blind, NRX-101 vs. placebo, with robotic TMS
Estimated enrollment	400 participants
Condition studied	Treatment-resistant depression
FDA status of NRX-101 for this use	Investigational; not approved for treatment-resistant depression
Estimated primary completion	December 31, 2027
Estimated study completion	March 31, 2028
Recruitment status in the June 24, 2026 registry record	Not yet recruiting
Class action or claim form	None

What NRx Pharmaceuticals Is Testing With NRX-101 and Robotic TMS

SPARC-TMS tests whether NRX-101 can improve results when added to robotic TMS for people whose depression has not responded well to earlier treatment.

NRX-101 is an oral fixed-dose combination of D-cycloserine and lurasidone. NRx says the FDA previously gave it Breakthrough Therapy Designation, and the company has studied it in bipolar depression with suicidal ideation. TMS is a noninvasive treatment that uses magnetic fields to stimulate targeted areas of the brain. SPARC-TMS adds robotic targeting to the stimulation.

NRx has described SPARC-TMS as a continuation of earlier DARPA-funded research at Harvard/McLean. Those earlier results come from the company’s own statements, and the new trial exists to test the idea more rigorously.

What the SPARC-TMS Trial Will Study

The ClinicalTrials.gov record describes a randomized, double-blind controlled study comparing NRX-101 with placebo in adults being treated with robotic TMS for treatment-resistant depression. The listed phase is Phase 2/Phase 3.

The June 24, 2026 record estimated:

• 400 participants;
• a September 1, 2026 study start;
• December 31, 2027 for primary completion; and
• March 31, 2028 for overall completion.

On a company earnings call, NRx said it expects about 240 patients to be enrolled at its HOPE clinics and at Harvard/McLean, and another 160 at military treatment facilities, all funded through the military. Those are the company’s expectations, not confirmed site lists.

What the $11,177,757.27 DARPA Contract Funds

The September 30 announcement describes an initial contract of $11,177,757.27 for SPARC-TMS. NRx Defense Systems, the subsidiary doing the work, was formed in April 2026 to develop treatments that pair D-cycloserine with TMS under robotic neuro-navigation.

The award came in steps. NRx disclosed in a Form 8-K that on July 21, 2026, DARPA’s Defense Sciences Office told the company its SPARC-TMS proposal had been selected for negotiation. NRx stated at the time that this was not a notice of award and that any award depended on negotiating final terms. In its second-quarter update, the company said it expected non-dilutive funding above $11.5 million, subject to completing contracting. The initial contract announced on September 30 is $11,177,757.27, so use that exact figure.

What the NRx Pharmaceuticals DARPA Award Does Not Mean for Patients

NRX-101 is not newly approved as a treatment for treatment-resistant depression, and it is not available to the public as one.

NRx’s filings say the FDA approved the SPARC-TMS trial protocol as a Phase 2/3 study. Companies sometimes shorthand this as an “FDA-approved trial.” That is permission to run the study. It is not approval of the drug for marketing, which would depend on the results and a later FDA review. NRx has said the trial could potentially serve as a registration study if the data support it. That is a future possibility the company describes, not a decision the FDA has made.

NRx has also reported that the FDA approved an Intermediate Population Expanded Access Protocol for NRX-101 as an add-on to accelerated TMS. Expanded access lets physicians request an investigational therapy for eligible patients outside a trial. It is not the same as marketing approval either.

What NRx Pharmaceuticals Has Said About Its Separate FDA Review of Preservative-Free Ketamine

The DARPA award is one of two separate tracks at NRx. The other is preservative-free ketamine.

On September 15, 2026, NRx announced that the FDA had reclassified an amendment to its Abbreviated New Drug Application (ANDA) from major to minor, with a revised GDUFA goal date of November 10, 2026. In August, NRx said the FDA had completed its first-cycle review without major deficiencies tied to the drug product, ingredients, proposed labeling or manufacturing controls, with the remaining issue being manufacturer certification for the vial.

An ANDA is a pathway for certain generic drugs, and its outcome is unrelated to the SPARC-TMS trial of NRX-101. For background on how ketamine is classified, see Are Schedule 3 Drugs Legal? What You Need to Know and How Are They Regulated?. That article covers federal controlled-substance rules and does not mean NRx’s product has been approved.

What Robotic TMS Means in the NRx Pharmaceuticals SPARC-TMS Program

On September 11, 2026, NRx’s subsidiary HOPE Therapeutics said it was starting training and deployment of the Zeta TMS Robotic System, which the company says received FDA 510(k) clearance in July 2026. The company describes it as using a robotic arm and AI-driven software to track patient movement and adjust the TMS coil in real time. NRx said the system supports SPARC-TMS and that HOPE’s clinical team was training ahead of deployment at its Florida clinics.

FDA clearance of a medical device is not FDA approval of NRX-101 as a drug. They follow different regulatory paths.

What the NRx Pharmaceuticals Development Means for People With Treatment-Resistant Depression

For now, the impact on patients is limited, because the treatment combination is still being studied and no results have been reported. If you are in treatment for depression, don’t change or stop your care because of this announcement; talk to your prescriber about any decision.

If you’re interested in SPARC-TMS, check the current ClinicalTrials.gov record for NCT07227103 for recruitment status, eligibility rules and locations. The June 24, 2026 record listed the study as not yet recruiting, and NRx says enrollment will follow the contract award. Recruitment details can change as sites open, so confirm with the registry or a listed site before assuming enrollment is available near you.

NRx Pharmaceuticals SPARC-TMS and DARPA Award: Key Dates

Date	Event
April 2026	NRx announces the formation of NRx Defense Systems, Inc.
June 24, 2026	Date of the ClinicalTrials.gov record listing SPARC-TMS as not yet recruiting
July 21, 2026	DARPA notifies NRx Defense Systems that SPARC-TMS was selected for contract negotiation
August 7, 2026	NRx reports the FDA’s first-cycle review of its preservative-free ketamine ANDA
September 1, 2026	Estimated study start in the June 2026 registry record
September 11, 2026	HOPE Therapeutics announces training and deployment of the Zeta TMS Robotic System
September 15, 2026	NRx announces the revised November 10, 2026 GDUFA goal date for preservative-free ketamine
September 30, 2026	NRx announces the $11,177,757.27 DARPA contract
November 10, 2026	Reported FDA GDUFA goal date for the preservative-free ketamine ANDA
December 31, 2027	Estimated primary completion of SPARC-TMS
March 31, 2028	Estimated overall completion of SPARC-TMS

NRx Pharmaceuticals $11.18M DARPA Award FAQ

What is the NRx Pharmaceuticals $11.18 million DARPA award?

It is an initial DARPA contract worth $11,177,757.27 awarded to NRx Defense Systems to fund SPARC-TMS, a trial of NRX-101 with robotic TMS for treatment-resistant depression.

What is NRx Pharmaceuticals testing in the SPARC-TMS trial?

NRX-101 compared with placebo in adults being treated with robotic TMS for treatment-resistant depression. It is a randomized, double-blind Phase 2/3 study with an estimated 400 participants.

Is NRX-101 FDA approved for treatment-resistant depression?

No. NRX-101 is investigational for this use. The FDA approved the trial protocol, which lets the study run, but that is not marketing approval of the drug.

What is the ClinicalTrials.gov number for the NRx Pharmaceuticals SPARC-TMS trial?

NCT07227103.

Can patients enroll in the NRx Pharmaceuticals SPARC-TMS trial?

NRx says enrollment will begin following the award. The June 24, 2026 registry record listed the study as not yet recruiting, so check the current ClinicalTrials.gov entry or a listed study site for the latest status.

Is there an NRx Pharmaceuticals class action, settlement or claim form tied to the DARPA award?

No. The DARPA contract is government funding for clinical research. It creates no settlement fund, compensation program or public claim process.

What is NRx Pharmaceuticals’ November 10, 2026 FDA date?

It is the revised GDUFA goal date NRx reported for its preservative-free ketamine ANDA. It is separate from the SPARC-TMS trial.

Does the DARPA award mean NRX-101 is commercially available?

No. The award funds research. Whether NRX-101 can ever be marketed for treatment-resistant depression depends on the trial results and FDA review.

When will the NRx Pharmaceuticals SPARC-TMS trial finish?

The June 2026 registry record estimated primary completion on December 31, 2027 and overall completion on March 31, 2028. These are estimates and can change.

What to Watch Next From NRx Pharmaceuticals

Keep three developments separate: recruitment and results in SPARC-TMS; the FDA’s decision on the preservative-free ketamine ANDA, with its November 10, 2026 goal date; and whether SPARC-TMS produces evidence strong enough for NRx to seek FDA approval for NRX-101 with TMS. Until then, the $11.18 million is funding for development, not proof that the treatment works.

Sources for the NRx Pharmaceuticals DARPA and FDA Developments

1. GlobeNewswire: NRx Defense Systems awarded DARPA prime contract (September 30, 2026): contract amount and project description.
2. NRx Pharmaceuticals Form 8-K (July 22, 2026): DARPA’s selection for negotiation, trial protocol and NCT07227103.
3. ClinicalTrials.gov: NCT07227103: design, enrollment estimate and timeline.
4. NRx Pharmaceuticals second-quarter 2026 results: DARPA prime-contractor selection and anticipated funding.
5. NRx Pharmaceuticals: FDA revises ketamine ANDA amendment (September 15, 2026): November 10, 2026 GDUFA goal date.
6. NRx Pharmaceuticals: HOPE Therapeutics robotic TMS (September 11, 2026): Zeta TMS Robotic System.
7. NRx Pharmaceuticals: FDA completes first-cycle ketamine ANDA review (August 7, 2026): first-cycle review status.

Disclaimer: This article is for information only and is not medical or legal advice. Trial status, FDA timelines and regulatory decisions can change, and NRx’s statements about possible future approvals are not guarantees.

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against NRx Pharmaceuticals’ official announcements and SEC filings, and the ClinicalTrials.gov record for NCT07227103, as of October 1, 2026. Last Updated: October 1, 2026.